Global Hypogonadism Drug Market Growth 2025-2031

Publication ID:

LPI03258574

Publication Date:

March 5, 2025

Pages:

131

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Hypogonadism Drug market size is predicted to grow from US$ 3847 million in 2025 to US$ 5335 million in 2031; it is expected to grow at a CAGR of 5.6% from 2025 to 2031.
There are two drugs for treatment of hypogonadism, one is testosterone replacement therapy drug; The other is used for gonadotropin treatment, which aims to maintain the normal development of male secondary sexual characteristics and restore fertility.
Rising population and rising incidence and prevalence of chronic diseases such as diabetes and obesity drive the market growth. According to clinical studies, the testosterone levels of men aged 60-80 are 20% and 80% lower than those of young men, respectively. Hypogonadism is most common in men over the age of 60. In countries such as Japan, China, and the U.S., the demand for male hypogonadism treatment has surged due to rising geriatric population and surging infertility rates.
The 鈥淗ypogonadism Drug Industry Forecast鈥� looks at past sales and reviews total world Hypogonadism Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Hypogonadism Drug sales for 2025 through 2031. With Hypogonadism Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Hypogonadism Drug industry.
This Insight Report provides a comprehensive analysis of the global Hypogonadism Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Hypogonadism Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Hypogonadism Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Hypogonadism Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Hypogonadism Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Hypogonadism Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Injection
Capsule
Segmentation by Application:
Hospital
Pharmacy
Specialist Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Allergan
AbbVie
Endo Pharmaceuticals
Pfizer Inc.
Clarus Therapeutics, Inc.
Aytu BioScience, Inc.
Antares Pharma
Upsher-Smith Laboratories, Inc.
Beijing Shuanghe Pharmaceutical Co., Ltd
Tianjin Jinyao Amino Acid Co., Ltd
Shanghai General Pharmaceutical Co., Ltd
Tianjin Lisheng Pharmaceutical Co., Ltd
Chengde Jiulong Pharmaceutical Co., Ltd
Harbin Pharmaceutical Group
Shenyang Keda Pharmaceutical Co., Ltd
Zhejiang Xianju Pharmaceutical Co., Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Hypogonadism Drug market?
What factors are driving Hypogonadism Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Hypogonadism Drug market opportunities vary by end market size?
How does Hypogonadism Drug break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hypogonadism Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Hypogonadism Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Hypogonadism Drug by Country/Region, 2020, 2024 & 2031
2.2 Hypogonadism Drug Segment by Type
2.2.1 Injection
2.2.2 Capsule
2.3 Hypogonadism Drug Sales by Type
2.3.1 Global Hypogonadism Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Hypogonadism Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Hypogonadism Drug Sale Price by Type (2020-2025)
2.4 Hypogonadism Drug Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.4.3 Specialist Clinic
2.4.4 Others
2.5 Hypogonadism Drug Sales by Application
2.5.1 Global Hypogonadism Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Hypogonadism Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Hypogonadism Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Hypogonadism Drug Breakdown Data by Company
3.1.1 Global Hypogonadism Drug Annual Sales by Company (2020-2025)
3.1.2 Global Hypogonadism Drug Sales Market Share by Company (2020-2025)
3.2 Global Hypogonadism Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Hypogonadism Drug Revenue by Company (2020-2025)
3.2.2 Global Hypogonadism Drug Revenue Market Share by Company (2020-2025)
3.3 Global Hypogonadism Drug Sale Price by Company
3.4 Key Manufacturers Hypogonadism Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Hypogonadism Drug Product Location Distribution
3.4.2 Players Hypogonadism Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Hypogonadism Drug by Geographic Region
4.1 World Historic Hypogonadism Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Hypogonadism Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Hypogonadism Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Hypogonadism Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Hypogonadism Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Hypogonadism Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Hypogonadism Drug Sales Growth
4.4 APAC Hypogonadism Drug Sales Growth
4.5 Europe Hypogonadism Drug Sales Growth
4.6 Middle East & Africa Hypogonadism Drug Sales Growth
5 Americas
5.1 Americas Hypogonadism Drug Sales by Country
5.1.1 Americas Hypogonadism Drug Sales by Country (2020-2025)
5.1.2 Americas Hypogonadism Drug Revenue by Country (2020-2025)
5.2 Americas Hypogonadism Drug Sales by Type (2020-2025)
5.3 Americas Hypogonadism Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Hypogonadism Drug Sales by Region
6.1.1 APAC Hypogonadism Drug Sales by Region (2020-2025)
6.1.2 APAC Hypogonadism Drug Revenue by Region (2020-2025)
6.2 APAC Hypogonadism Drug Sales by Type (2020-2025)
6.3 APAC Hypogonadism Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Hypogonadism Drug by Country
7.1.1 Europe Hypogonadism Drug Sales by Country (2020-2025)
7.1.2 Europe Hypogonadism Drug Revenue by Country (2020-2025)
7.2 Europe Hypogonadism Drug Sales by Type (2020-2025)
7.3 Europe Hypogonadism Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Hypogonadism Drug by Country
8.1.1 Middle East & Africa Hypogonadism Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Hypogonadism Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Hypogonadism Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Hypogonadism Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Hypogonadism Drug
10.3 Manufacturing Process Analysis of Hypogonadism Drug
10.4 Industry Chain Structure of Hypogonadism Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Hypogonadism Drug Distributors
11.3 Hypogonadism Drug Customer
12 World Forecast Review for Hypogonadism Drug by Geographic Region
12.1 Global Hypogonadism Drug Market Size Forecast by Region
12.1.1 Global Hypogonadism Drug Forecast by Region (2026-2031)
12.1.2 Global Hypogonadism Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Hypogonadism Drug Forecast by Type (2026-2031)
12.7 Global Hypogonadism Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Allergan
13.1.1 Allergan Company Information
13.1.2 Allergan Hypogonadism Drug Product Portfolios and Specifications
13.1.3 Allergan Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Allergan Main Business Overview
13.1.5 Allergan Latest Developments
13.2 AbbVie
13.2.1 AbbVie Company Information
13.2.2 AbbVie Hypogonadism Drug Product Portfolios and Specifications
13.2.3 AbbVie Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 AbbVie Main Business Overview
13.2.5 AbbVie Latest Developments
13.3 Endo Pharmaceuticals
13.3.1 Endo Pharmaceuticals Company Information
13.3.2 Endo Pharmaceuticals Hypogonadism Drug Product Portfolios and Specifications
13.3.3 Endo Pharmaceuticals Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Endo Pharmaceuticals Main Business Overview
13.3.5 Endo Pharmaceuticals Latest Developments
13.4 Pfizer Inc.
13.4.1 Pfizer Inc. Company Information
13.4.2 Pfizer Inc. Hypogonadism Drug Product Portfolios and Specifications
13.4.3 Pfizer Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Pfizer Inc. Main Business Overview
13.4.5 Pfizer Inc. Latest Developments
13.5 Clarus Therapeutics, Inc.
13.5.1 Clarus Therapeutics, Inc. Company Information
13.5.2 Clarus Therapeutics, Inc. Hypogonadism Drug Product Portfolios and Specifications
13.5.3 Clarus Therapeutics, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Clarus Therapeutics, Inc. Main Business Overview
13.5.5 Clarus Therapeutics, Inc. Latest Developments
13.6 Aytu BioScience, Inc.
13.6.1 Aytu BioScience, Inc. Company Information
13.6.2 Aytu BioScience, Inc. Hypogonadism Drug Product Portfolios and Specifications
13.6.3 Aytu BioScience, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Aytu BioScience, Inc. Main Business Overview
13.6.5 Aytu BioScience, Inc. Latest Developments
13.7 Antares Pharma
13.7.1 Antares Pharma Company Information
13.7.2 Antares Pharma Hypogonadism Drug Product Portfolios and Specifications
13.7.3 Antares Pharma Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Antares Pharma Main Business Overview
13.7.5 Antares Pharma Latest Developments
13.8 Upsher-Smith Laboratories, Inc.
13.8.1 Upsher-Smith Laboratories, Inc. Company Information
13.8.2 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Product Portfolios and Specifications
13.8.3 Upsher-Smith Laboratories, Inc. Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Upsher-Smith Laboratories, Inc. Main Business Overview
13.8.5 Upsher-Smith Laboratories, Inc. Latest Developments
13.9 Beijing Shuanghe Pharmaceutical Co., Ltd
13.9.1 Beijing Shuanghe Pharmaceutical Co., Ltd Company Information
13.9.2 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolios and Specifications
13.9.3 Beijing Shuanghe Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Beijing Shuanghe Pharmaceutical Co., Ltd Main Business Overview
13.9.5 Beijing Shuanghe Pharmaceutical Co., Ltd Latest Developments
13.10 Tianjin Jinyao Amino Acid Co., Ltd
13.10.1 Tianjin Jinyao Amino Acid Co., Ltd Company Information
13.10.2 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Product Portfolios and Specifications
13.10.3 Tianjin Jinyao Amino Acid Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Tianjin Jinyao Amino Acid Co., Ltd Main Business Overview
13.10.5 Tianjin Jinyao Amino Acid Co., Ltd Latest Developments
13.11 Shanghai General Pharmaceutical Co., Ltd
13.11.1 Shanghai General Pharmaceutical Co., Ltd Company Information
13.11.2 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolios and Specifications
13.11.3 Shanghai General Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Shanghai General Pharmaceutical Co., Ltd Main Business Overview
13.11.5 Shanghai General Pharmaceutical Co., Ltd Latest Developments
13.12 Tianjin Lisheng Pharmaceutical Co., Ltd
13.12.1 Tianjin Lisheng Pharmaceutical Co., Ltd Company Information
13.12.2 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolios and Specifications
13.12.3 Tianjin Lisheng Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Tianjin Lisheng Pharmaceutical Co., Ltd Main Business Overview
13.12.5 Tianjin Lisheng Pharmaceutical Co., Ltd Latest Developments
13.13 Chengde Jiulong Pharmaceutical Co., Ltd
13.13.1 Chengde Jiulong Pharmaceutical Co., Ltd Company Information
13.13.2 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolios and Specifications
13.13.3 Chengde Jiulong Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Chengde Jiulong Pharmaceutical Co., Ltd Main Business Overview
13.13.5 Chengde Jiulong Pharmaceutical Co., Ltd Latest Developments
13.14 Harbin Pharmaceutical Group
13.14.1 Harbin Pharmaceutical Group Company Information
13.14.2 Harbin Pharmaceutical Group Hypogonadism Drug Product Portfolios and Specifications
13.14.3 Harbin Pharmaceutical Group Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Harbin Pharmaceutical Group Main Business Overview
13.14.5 Harbin Pharmaceutical Group Latest Developments
13.15 Shenyang Keda Pharmaceutical Co., Ltd
13.15.1 Shenyang Keda Pharmaceutical Co., Ltd Company Information
13.15.2 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolios and Specifications
13.15.3 Shenyang Keda Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Shenyang Keda Pharmaceutical Co., Ltd Main Business Overview
13.15.5 Shenyang Keda Pharmaceutical Co., Ltd Latest Developments
13.16 Zhejiang Xianju Pharmaceutical Co., Ltd
13.16.1 Zhejiang Xianju Pharmaceutical Co., Ltd Company Information
13.16.2 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Product Portfolios and Specifications
13.16.3 Zhejiang Xianju Pharmaceutical Co., Ltd Hypogonadism Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Zhejiang Xianju Pharmaceutical Co., Ltd Main Business Overview
13.16.5 Zhejiang Xianju Pharmaceutical Co., Ltd Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂